13 unchanged sentences
The NASDAQ Composite Index tracks the aggregate price performance of equity securities traded on The NASDAQ Stock Market.
−Removed: The NASDAQ Health Care Index and NASDAQ Health Services Index tracks the aggregate price performance of health care and health services equity securities.
+Added: The NASDAQ Health Care Index and NASDAQ Health Services Index tracks the aggregate price performance of healthcare and health services equity securities.
Omnicell’s common stock is traded on The NASDAQ Global Select Market and is a component of both indexes.
−Removed: The stock price performance shown on the graph is based on historical results and is not necessarily indicative of future price performance.
+Added: The stock price performance shown on the graph is based on historical results and should not be relied upon as an indication of future price performance.
COMPARISON OF 5 YEAR CUMULATIVE TOTAL RETURN (1) (2)
13 unchanged sentences
Stock Repurchase Program
−Removed: On September 17, 2020, the Board of Directors authorized a one-time stock repurchase transaction providing for the repurchase of up to $75.0 million of our common stock in privately negotiated transactions concurrently with the issuance of the convertible senior notes, described in Note 10, Convertible Senior Notes, of the Notes to Consolidated Financial Statements in this annual report on Form 10-K.
−Removed: In September 2020, we repurchased 749,300 shares of our common stock from purchasers of the convertible senior notes in the offering in privately negotiated transactions effected through one of the initial purchasers or its affiliate at an average price of $70.78 per share for an aggregate purchase price of approximately $53.0 million.
−Removed: There will be no further repurchases under this one-time authorization.
−Removed: There were no other repurchases of our outstanding common stock
−Removed: during the year ended December 31, 2020, including under our current stock repurchase programs.
+Added: We did not repurchase any shares of our common stock during the year ended December 31, 2021.
Refer to Note 15, Stock Repurchase Program , of the Notes to Consolidated Financial Statements in this Annual Report on Form 10-K for additional information.
Equity Offerings
−Removed: For the year ended December 31, 2020, we did not sell any of our common stock under our Distribution Agreement.
Refer to Note 16, Equity Offerings , of the Notes to Consolidated Financial Statements in this Annual Report on Form 10-K for additional information.
−Removed: SELECTED FINANCIAL DATA
−Removed: The following selected consolidated financial data is derived from our Consolidated Financial Statements.
−Removed: This data should be read in conjunction with our Consolidated Financial Statements and related Notes included in this annual report on Form 10-K and with Item 7, Management's Discussion and Analysis of Financial Condition and Results of Operations .
−Removed: Historical results may not be indicative of future results.
−Removed: Year Ended December 31,
−Removed: 2019 2018 2017 (2) (4)
−Removed: (In thousands, except per share amounts)
−Removed: Consolidated Statements of Operations Data
−Removed: Total revenues $ 892,208 $ 897,027 $ 787,309 $ 712,714 $ 695,908
−Removed: Gross profit 413,292 436,912 372,330 318,637 317,085
−Removed: Income from operations 35,526 78,352 44,392 11,145 21,405
−Removed: Net income $ 32,194 $ 61,338 $ 37,729 $ 30,518 $ 9,756
−Removed: Net income per share:
−Removed: Basic $ 0.76 $ 1.48 $ 0.96 $ 0.81 $ 0.27
−Removed: Diluted $ 0.74 $ 1.43 $ 0.93 $ 0.79 $ 0.26
−Removed: Shares Used in Per Share Calculations
−Removed: Basic 42,583 41,462 39,242 37,483 36,156
−Removed: Diluted 43,743 42,943 40,559 38,712 36,864
−Removed: 2019 2018 2017 (2) (4)
−Removed: (In thousands)
−Removed: Consolidated Balance Sheet Data
−Removed: Total assets $ 1,824,504 $ 1,240,810 $ 1,081,242 $ 1,016,362 $ 966,884
−Removed: Long-term debt (5)
−Removed: 467,201 50,000 135,417 194,917 245,731
−Removed: Total liabilities 857,001 395,556 401,625 462,021 508,048
−Removed: Total stockholders’ equity $ 967,503 $ 845,254 $ 679,617 $ 554,341 $ 458,836
−Removed: __________________________________________________
−Removed: (1) Includes 340B Link Business financial results as of October 2020, the acquisition date.
−Removed: (2) Includes InPharmics financial results as of April 2017, the acquisition date.
−Removed: (3) Includes Aesynt and Ateb financial results as of the acquisition dates of January 2016 and December 2016, respectively.
−Removed: (4) As adjusted for full retrospective adoption of Accounting Standards Codification 606, Revenue from Contracts with Customers .
−Removed: (5) Consists of the revolving credit facility and convertible senior notes, net.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.